| Item Type | Name |
|
Academic Article
|
Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease.
|
|
Academic Article
|
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
|
|
Academic Article
|
Gene marking after bone marrow transplantation.
|
|
Academic Article
|
Adoptive cellular immunotherapy for EBV lymphoproliferative disease.
|
|
Academic Article
|
Cytotoxic T cells and immunotherapy.
|
|
Academic Article
|
EBV specific CTL: a model for immune therapy.
|
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers.
|
|
Academic Article
|
Gene and cell transfer for specific immunotherapy.
|
|
Academic Article
|
Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
|
|
Academic Article
|
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes.
|
|
Academic Article
|
Induction of vigorous helper and cytotoxic T cell as well as B cell responses by dendritic cells expressing a modified antigen targeting receptor-mediated internalization pathway.
|
|
Academic Article
|
Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines.
|
|
Academic Article
|
Immunotherapy for Hodgkin's disease.
|
|
Academic Article
|
Targeting CD19 with genetically modified EBV-specific human T lymphocytes.
|
|
Academic Article
|
An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
|
|
Academic Article
|
Large-scale expansion of dendritic cell-primed polyclonal human cytotoxic T-lymphocyte lines using lymphoblastoid cell lines for adoptive immunotherapy.
|
|
Academic Article
|
Extensive cross-reactivity of adenovirus-specific cytotoxic T cells.
|
|
Academic Article
|
Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells.
|
|
Academic Article
|
Autoimmune disease induced by dendritic cell immunization against leukemia.
|
|
Academic Article
|
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
|
|
Academic Article
|
Immunotherapy to reconstitute immunity to DNA viruses.
|
|
Academic Article
|
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes.
|
|
Academic Article
|
An inducible caspase 9 safety switch for T-cell therapy.
|
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
|
|
Academic Article
|
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
|
|
Academic Article
|
Suicide genes as safety switches in T lymphocytes.
|
|
Academic Article
|
Adenoviral infections in hematopoietic stem cell transplantation.
|
|
Academic Article
|
Adoptive immunotherapy for Hodgkin's lymphoma.
|
|
Academic Article
|
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applications.
|
|
Academic Article
|
Immune therapy for EBV infections after hemopoietic stem-cell transplant.
|
|
Academic Article
|
Immunotherapy for Epstein-Barr virus-associated cancers in children.
|
|
Academic Article
|
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
|
|
Academic Article
|
Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy.
|
|
Academic Article
|
Adoptive cellular immunotherapy for viral diseases.
|
|
Academic Article
|
Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
|
|
Academic Article
|
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
|
|
Academic Article
|
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
|
|
Academic Article
|
Adoptive immunotherapy for posttransplantation viral infections.
|
|
Academic Article
|
Genome-wide mapping of PiggyBac transposon integrations in primary human T cells.
|
|
Academic Article
|
Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes.
|
|
Academic Article
|
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.
|
|
Academic Article
|
Options for T-cell based therapies.
|
|
Academic Article
|
Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.
|
|
Academic Article
|
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
|
|
Academic Article
|
Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.
|
|
Academic Article
|
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients.
|
|
Academic Article
|
Inducible apoptosis as a safety switch for adoptive cell therapy.
|
|
Academic Article
|
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.
|
|
Academic Article
|
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma.
|
|
Academic Article
|
Hitchhiker's guide to the T cell.
|
|
Academic Article
|
Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections.
|
|
Academic Article
|
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma.
|
|
Academic Article
|
T cell therapies.
|
|
Academic Article
|
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
|
|
Academic Article
|
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.
|
|
Academic Article
|
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation.
|
|
Academic Article
|
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy.
|
|
Academic Article
|
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.
|
|
Academic Article
|
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
|
|
Academic Article
|
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.
|
|
Academic Article
|
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
|
|
Academic Article
|
Generation of multivirus-specific T cells to prevent/treat viral infections after allogeneic hematopoietic stem cell transplant.
|
|
Academic Article
|
Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.
|
|
Academic Article
|
A Th1-inducing adenoviral vaccine for boosting adoptively transferred T cells.
|
|
Academic Article
|
Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
|
|
Academic Article
|
Thunder and lightning: immunotherapy and oncolytic viruses collide.
|
|
Academic Article
|
Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.
|
|
Academic Article
|
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
|
|
Academic Article
|
Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation.
|
|
Academic Article
|
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
|
|
Academic Article
|
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
|
|
Academic Article
|
Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
|
|
Academic Article
|
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
|
|
Academic Article
|
Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
|
|
Academic Article
|
T-cell therapy in the treatment of post-transplant lymphoproliferative disease.
|
|
Academic Article
|
Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma.
|
|
Academic Article
|
Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies.
|
|
Academic Article
|
Control of virus-induced lymphoproliferation: Epstein-Barr virus-induced lymphoproliferation and host immunity.
|
|
Academic Article
|
Adoptive immunotherapy for Epstein-Barr virus-related lymphoma.
|
|
Academic Article
|
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
|
|
Academic Article
|
Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15.
|
|
Academic Article
|
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
|
|
Academic Article
|
Adoptive immunotherapy for EBV-associated malignancies.
|
|
Academic Article
|
Improving T cell therapy for cancer.
|
|
Academic Article
|
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation.
|
|
Academic Article
|
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer.
|
|
Academic Article
|
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.
|
|
Academic Article
|
Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host.
|
|
Academic Article
|
Developments in clinical cell therapy.
|
|
Academic Article
|
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b.
|
|
Academic Article
|
Enhancement of dendritic cells as vaccines for cancer.
|
|
Academic Article
|
Adoptive transfer of virus-directed T cells: will this fly for flu?
|
|
Academic Article
|
Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.
|
|
Concept
|
Immunotherapy
|
|
Concept
|
Immunotherapy, Adoptive
|
|
Academic Article
|
Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy.
|
|
Academic Article
|
T lymphocytes targeting native receptors.
|
|
Academic Article
|
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene.
|
|
Academic Article
|
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins.
|
|
Academic Article
|
Systemic inflammatory response syndrome after administration of unmodified T lymphocytes.
|
|
Academic Article
|
Harnessing the immune system to potentiate oncolytics.
|
|
Academic Article
|
Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in?vivo cytokine administration: implications for clinical therapy.
|
|
Academic Article
|
Reply to S. Yuan et al.
|
|
Academic Article
|
Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Toward immunotherapy with redirected T cells in a large animal model: ex vivo activation, expansion, and genetic modification of canine T cells.
|
|
Academic Article
|
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
|
|
Academic Article
|
Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients.
|
|
Academic Article
|
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
|
|
Academic Article
|
Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.
|
|
Academic Article
|
Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.
|
|
Academic Article
|
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
|
|
Academic Article
|
Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.
|
|
Academic Article
|
Antigen-specific T cell therapies for cancer.
|
|
Academic Article
|
Adoptive T-Cell Immunotherapy.
|
|
Academic Article
|
Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes.
|
|
Academic Article
|
EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
|
|
Academic Article
|
Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer.
|
|
Academic Article
|
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
|
|
Academic Article
|
Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.
|
|
Academic Article
|
Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells.
|
|
Academic Article
|
Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1.
|
|
Academic Article
|
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
|
|
Academic Article
|
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma.
|
|
Academic Article
|
Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.
|
|
Academic Article
|
Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
|
|
Academic Article
|
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
|
|
Grant
|
ENHANCING T CELL THERAPY OF CANCER
|
|
Academic Article
|
In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
|
|
Academic Article
|
T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.
|
|
Academic Article
|
T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells.
|
|
Academic Article
|
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma.
|
|
Academic Article
|
Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas.
|
|
Academic Article
|
Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study.
|
|
Academic Article
|
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity.
|
|
Academic Article
|
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.
|
|
Academic Article
|
A Costimulatory CAR Improves TCR-based Cancer Immunotherapy.
|
|
Academic Article
|
Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
|
|
Academic Article
|
Structural surfaceomics reveals an AML-specific conformation of integrin ?2 as a CAR T cellular therapy target.
|